Stereoselective pharmacokinetic and pharmacodynamic analysis of a CNS-active sulphamoylphenyl carbamate derivative

References

• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010;9:68–83.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia 2018;59:1811–41.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia 2018;59:1842–66.
   PubMed Web of Science ®Google Scholar
• Bibi D, Mawasi H, Nocentini A, et al. Design and comparative evaluation of the anticonvulsant profile, carbonic-anhydrate inhibition and teratogenicity of novel carbamate derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. Neurochem Res 2017;42:1972–82.
   PubMed Web of Science ®Google Scholar
• Brocks DR. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm Drug Disposit 2006;27:387–406.
   PubMed Web of Science ®Google Scholar
• Levy RH, Boddy AV. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991;8:551–6.
   PubMed Web of Science ®Google Scholar
• Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002;1:753–68.
   PubMed Web of Science ®Google Scholar
• Mawasi H, Bibi D, Shekh-Ahmad T, et al. Pharmacokinetic-pharmacodynamic correlation and brain penetration of sec-butylpropylacetamide, a new CNS drug possessing unique activity against status epilepticus. Mol Pharm 2016;13:2492–6.
   PubMed Web of Science ®Google Scholar
• Hen N, Shekh-Ahmad T, Yagen B, et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013;56:6467–77.
   PubMed Web of Science ®Google Scholar
• Shekh-Ahmad T, Hen N, Yagen B, et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 2014;55:353–61.
   PubMed Web of Science ®Google Scholar
• Shekh-Ahmad T, Mawasi H, McDonough JH, et al. The potential of valnoctamide and sec-butylpropylacetamide (SPD) for acute seizures and status epilepticus (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav 2015;49:298–302.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• (a) Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841–5.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin Ther Pat 2003;13:1545–50.
   Web of Science ®Google Scholar
  (c) Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigations on native and cobalt-substituted enzymes. Eur J Med Chem 1996;31:1001–10.
   Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 2005;15:2315–20.
   PubMed Web of Science ®Google Scholar
• (a) Temperini C, Innocenti A, Scozzafava A, et al. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example. J Med Chem 2010;53:850–4.
   PubMed Web of Science ®Google Scholar
  (b) Clare BW, Supuran CT. Carbonic anhydrase activators. Part 3. Structure-activity correlations for a series of isozyme II activators. J Pharm Sci 1994;83:768–73.
   PubMed Web of Science ®Google Scholar
• Pellock JM, Perhach JM, Sofia RD. Felbamate. In: Levy RH, Mattson RH, Meldrum BS, et al. eds. Antiepileptic drugs. 5nd ed. Philadelphia (PA): Lipincott Williams & Wilkins Co.; 2002.
   Google Scholar
• Thakkar K, Billa G, Rane J, et al. The rise and fall of felbamate as a treatment for partial epilepsy - aplastic anemia and hepatic failure to blame? Expert Rev Neurother 2015;15:1373–5.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1–43.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the tenth Eilat conference (EILAT X). Epilepsy Res 2010;92:89–124.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the eleventh Eilat conference (EILAT XI). Epilepsy Res 2013;103:2–30.
   PubMed Web of Science ®Google Scholar
• Krauss G, French J, Kamin J, et al. Seizure freedom with YKP3089 as adjunctive therapy for refractory partial-onset seizures in double-blind placebo-controlled trials. Neurology 2016;86:2–19.
   Web of Science ®Google Scholar
• Sperling MR, Klein P, Kamin M. Safety of cenobamate (YKP3089) as adjunctive treatment for uncontrolled partial (focal) seizures: results from a large, phase 3, multicenter, open-label study. AES Meeting; 2018 Nov 30–Dec 4; New Orleans (LA).
   Google Scholar
• SK Life Sciences Press Release on February, 4th, 2019.
   Google Scholar
• (a) Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Patent 2018;28:713–21.
   PubMed Web of Science ®Google Scholar
  (b) Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31.
   PubMed Web of Science ®Google Scholar
• Resor SR, Resor LD, Woodbury DM, Kemp JW. Acetazolamide. In: Levy RH, Mattson RH, Meldrum B, et al., eds.. Antiepileptic drugs. 4th ed. Winnipeg, Canada: Raven Press Co.; 1995.
   Google Scholar
• Kwan SY, Chuang YC, Huang CW, et al. Zonisamide: review of recent clinical evidence for treatment of epilepsy. CNS Neurosci Ther 2015;21:683–91.
   PubMed Web of Science ®Google Scholar
• Mula M. Emerging drugs for focal epilepsy. Expert Opin Emerg Drugs 2018;23:243–9.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Yajima N, Kiyoshi T, et al. N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate. Biorg Med Chem Lett 2017;27:4118–21.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Yajima N, Kiyoshi T, et al. Identification of 2-(2'-fluoro-[1,1'-biphenyl]-2-yl)acetamide as a sodium valproate-like broad spectrum anti-epileptic drug candidate. Bioorg Med Chem Lett 2019;29:138–42.
   PubMed Web of Science ®Google Scholar
• Sethl KK, Nayak PN, Sarker H, et al. A rational approach toward the development of human carbonic anhydrase inhibitors as antiepileptic agents. Med Chem 2016;6:405–10.
   Google Scholar
• Ajeet A, Kumar A, Mishra AK. Design, synthesis and pharmacological evaluation of sulfonamide derivatives screened against maximal electroshock seizure test. Mol Biol 2018;7:206–15.
   Google Scholar
• Agranat I, Wainschtein SR. The strategy of enantiomer patents of drugs. Drug Discov Today 2010;15:163–70.
   PubMed Web of Science ®Google Scholar
• Caner H, Groner E, Levy L, Agranat I. Trends in the drug development of chiral drugs. Drug Discov Today 2004;9:105–10.
   PubMed Web of Science ®Google Scholar